tafoxiparin (DF01) / Dilafor - LARVOL DELTA

Cervical Glycosaminoglycans and Extracellular Matrix Remodeling: New Insights and the Therapeutic Promise of Tafoxiparin. (PubMed, Cells) - "Although tafoxiparin may replicate some actions of endogenous GAGs, current clinical data remain sparse and inconclusive. Thus, targeting cervical GAG biology represents a mechanistic yet still investigational strategy, requiring further studies to determine its therapeutic value."

Journal • Review • Cervical Cancer • Inflammation

Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from 2 randomized, placebo-controlled studies. (PubMed, Am J Obstet Gynecol) - "Subcutaneous treatment with tafoxiparin before labor onset (study 1) may be effective in reducing the labor time among women undergoing labor induction and among those requiring oxytocin for slow progression of labor. Moreover, tafoxiparin may have a positive effect on cervical ripening. Short-term, intravenous treatment with tafoxiparin as an adjunct to oxytocin in patients with labor arrest (study 2) did not affect labor time or other endpoints. Both studies suggest that tafoxiparin has a favorable safety profile in mothers and their infants."

Clinical • Journal • Review • Obstetrics

Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: a letter. (PubMed, Am J Obstet Gynecol) - No abstract available

Journal

Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from two randomized, placebo-controlled studies: A reply. (PubMed, Am J Obstet Gynecol) - No abstract available

Journal

Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix (clinicaltrials.gov) - P2 | N=347 | Completed | Sponsor: Dilafor AB | Recruiting ➔ Completed | N=254 ➔ 347

Enrollment change • Trial completion

Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix (clinicaltrials.gov) - P2 | N=254 | Recruiting | Sponsor: Dilafor AB | Trial completion date: Jun 2022 ➔ Jan 2023 | Trial primary completion date: May 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date

Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix (clinicaltrials.gov) - P2; N=254; Recruiting; Sponsor: Dilafor AB; Trial completion date: Jan 2022 ➔ Jun 2022; Trial primary completion date: Mar 2021 ➔ May 2022

Clinical • Trial completion date • Trial primary completion date

Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest (clinicaltrials.gov) - P2; N=361; Completed; Sponsor: Dilafor AB; Active, not recruiting ➔ Completed

Clinical • Trial completion

Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix (clinicaltrials.gov) - P2; N=254; Recruiting; Sponsor: Dilafor AB; Trial completion date: Apr 2021 ➔ Jan 2022; Trial primary completion date: Apr 2020 ➔ Mar 2021

Clinical • Trial completion date • Trial primary completion date